{"contentid": 488528, "importid": NaN, "name": "Moderna offers 500 million doses for developing countries, but not this year", "introduction": "As India battles a surge in coronavirus cases, with over 20 million infections nationwide and hospitals running low on oxygen, there is a pressing need to bolster global vaccination efforts.", "content": "<p>As India battles a surge in coronavirus cases, with over 20 million infections nationwide and hospitals running low on oxygen, there is a pressing need to bolster global vaccination efforts.</p>\n<p>With this goal in mind, Moderna (Nasdaq: MRNA) has agreed to supply up to half a billion doses of its vaccine to Gavi, the Vaccine Alliance - a public&ndash;private global health partnership working on immunisation in lower-income countries.</p>\n<p>The Cambridge, USA-based mRNA specialist recently announced it would invest in both owned and partnered manufacturing facilities to boost global supplies of its coronavirus vaccine next year, targeting production of up to three billion doses.</p>\n<p>Chief executive St&eacute;phane Bancel said his firm supported &ldquo;COVAX&rsquo;s mission to ensure broad, affordable and equitable access to COVID-19 vaccines,&rdquo; adding &ldquo;we remain committed to doing everything that we can to ending this ongoing pandemic with our mRNA COVID-19 vaccine.&rdquo;</p>\n<h2>Vaccinating the world</h2>\n<p>Gavi is one of several global health bodies leading the COVAX initiative, a project to accelerate the development and manufacture of COVID-19 vaccines, and to support global access.</p>\n<p>As countries such as the UK and USA prepare to vaccinate ever younger demographics, and with approval for certain vaccines in children expected imminently, there has been criticism that rich countries are not doing enough to combat the novel coronavirus in the developing world.</p>\n<p>In the USA, there is no shortage of supplies of vaccine, with an estimated 65 million doses having been distributed but not yet administered, around half of which is from Pfizer (NYSE: PFE) and around 25 million doses of which are from Moderna.</p>\n<p>Moderna has agreed to supply Gavi with an initial 34 million doses to be delivered in the fourth quarter of 2021, providing an option on 466 million additional doses in 2022, with all doses offered at its lowest tiered price.</p>\n<p>Gavi CEO Seth Berkley said: &ldquo;We are very pleased to sign this new agreement with Moderna, giving COVAX Facility participants access to yet another highly efficacious vaccine.&rdquo;</p>\n<p>He added: &ldquo;Expanding and having a diverse portfolio has always been a core goal for COVAX, and to remain adaptable in the face of this continually evolving pandemic &ndash; including the rising threat posed by new variants. This agreement is a further step in that direction.&rdquo;</p>\n<p>Moderna's vaccine is the subject of recently-announced research - <a href=\"https://www.nejm.org/doi/full/10.1056/NEJMc2103916\" target=\"_blank\" rel=\"follow noopener\">published</a>&nbsp;in the New England Journal of Medicine - which shows that antibody activity remained high in all age groups beyond six months after a second dose.</p>", "date": "2021-05-04 11:21:00", "meta_title": NaN, "meta_keywords": "million, doses, global, Moderna, countries, vaccine, coronavirus, Gavi, developing, year, offers, oxygen, bolster, pressing, nationwide, running, hospitals", "meta_description": "As India battles a surge in coronavirus cases, with over 20 million infections nationwide and hospitals running low on oxygen, there is a pressing need to bolst", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-04 11:20:29", "updated": "2021-05-04 14:58:10", "access": NaN, "url": "https://www.thepharmaletter.com/article/moderna-offers-500-million-doses-for-developing-countries-but-not-this-year", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "moderna_therapeutics_large.jpg", "image2id": "moderna_therapeutics_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Deals, Focus On, Production, Public health", "geography_tag": "Global, USA", "company_tag": "Moderna", "drug_tag": "mRNA-1273", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-04 11:21:00"}